CHAPTER 1. INTRODUCTION
1.1.Market Definition
1.2.Executive Summary
1.3. The Scope of the Study
CHAPTER 2. RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3. MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2.Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5.Degree of Competition
3.3.PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4. MARKET DYNAMICS
4.1. Market Drivers
4.1.1. Increasing commercial demand for molecularly cloned products and recombinant
proteins
4.1.2. Advancements in molecular cloning research
4.2.Market Restraints & Challenges
4.2.1. Lack of skilled professionals
4.2.2. The high cost of competent cell kits
4.3.Market Opportunities
4.3.1. Emerging markets
4.3.2. Emerging applications of competent cells
CHAPTER 5. GLOBAL COMPONENT CELLS MARKET– BY TYPE
5.1. Introduction
5.2. Chemically competent cells
5.3. Electrocompetent Cells
CHAPTER 6. GLOBAL COMPONENT CELLS MARKET – BY APPLICATION
6.1. Introduction
6.2. Protein Expression
6.3. Other Applications
6.3.1 Mutagenesis
6.3.2 Large Plasmid Transformation
6.3.3 Single-Stranded DNA Production
6.3.4 Lentiviral Vector Production
6.4. Cloning
6.4.1. Subcloning & routine cloning
6.4.2. Phage display library construction
6.4.3. Toxic/unstable DNA cloning
6.4.4. High-throughput cloning
CHAPTER 7. GLOBAL COMPONENT CELLS MARKET – BY END USER
7.1. Introduction
7.2. Contract research organisations
7.3. Pharmaceutical & biotechnology companies
7.4. Academic research institutes
CHAPTER 8. GLOBAL COMPONENT CELLS MARKET - BY GEOGRAPHY
8.1. Introduction
8.2.North America
8.2.1. The U.S.
8.2.2. Canada
8.2.3. Mexico
8.2.4. Costa Rica
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Chile
8.3.4. Columbia
8.3.5. Others
8.4. Europe
8.4.1. U.K.
8.4.2. Germany
8.4.3. France
8.4.4. Italy
8.4.5. Spain
8.4.6. Russia
8.4.7. Netherlands
8.4.8. Switzerland
8.4.9. Poland
8.4.10. Others
8.5. APAC
8.5.1. China
8.5.2. Japan
8.5.3. India
8.5.4. South Korea
8.5.5. Australia & New Zealand
8.5.6. Malaysia
8.5.7. Singapore
8.5.8. Others
8.6. Middle East & Africa
8.6.1. UAE
8.6.2. Saudi Arabia
8.6.3. Iran
8.6.4. Iraq
8.6.5. Qatar
8.6.6. South Africa
8.6.7. Algeria
8.6.8. Morocco
8.6.9. Nigeria
8.6.10. Egypt
8.6.11. Others
CHAPTER 9. GLOBAL COMPONENT CELLS MARKET - COMPANY PROFILES
9.1. Origene Technologies, Inc.
9.2. Genscript Biotech Corporation
9.3. Promega Corporation
9.4. Takara Bio, Inc.
9.5. New England Biolabs, Inc.
9.6. Agilent Technologies, Inc.
9.7. TransGen Biotech, Inc.
9.8. Thermo Fisher Scientific, Inc.
9.9. Illumina, Inc.
9.10. Zymo Research
9.11. Qiagen N.V.
9.12. Bio-Rad Laboratories, Inc.
9.13. Merck KGaA
CHAPTER 10. GLOBAL COMPONENT CELLS MARKET - COMPETITIVE
LANDSCAPE
10.1. Market Share Analysis
10.2. Strategies adopted by top companies
10.3.Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 11. MARKET INSIGHTS
11.1. Industry Experts Insights
11.2. Analysts Opinions
11.3. Investment Opportunities
CHAPTER 12. APPENDIX
12.1. List of Tables
12.2. List of Figures
